Inflammation and other complications with dental implants are common. Results
from a double-blind randomized controlled trial in 34 patients with implants
show that 30 days of supplementation with Lactobacillus reuteri Prodentis
significantly reduced inflammation related to implants. This is the first
published data with Lactobacillus reuteri Prodentis in patients with dental
implants.
Peri-implant mucositis is an inflammatory condition affecting the gums around
dental implants. If not treated, it may lead to a worsened condition, peri
-implantitis, which may need surgery or replacement of the dental implant.
Nearly one out of five patients will suffer from peri-implantitis five to ten
years after the dental implants have been inserted. Currently there are no
consensus guidelines for the treatment of peri-implantitis.
“Our study shows that treatment with Lactobacillus reuteri Prodentis in patients
with implants and mucositis both improved clinical parameters as well as reduced
cytokine levels compared to placebo. Supplementation of Lactobacillus reuteri
Prodentis may therefore be a good alternative for both treatment of peri-implant
disease and its prevention”, says Antonio J Flichy-Fernández, DDS, PhD,
Department of Oral Surgery and Implantology, University of Valencia, Spain.
The study was published in Journal of Periodontal
Research (http://www.ncbi.nlm.nih.gov/pubmed/25712760) 25 February 2015. Study
details are found through the attached
link (http://www.biogaia.com/sites/biogaia.com/files/Study
-details_Flichy_2015.pdf).
“Ten years ago peri-implantitis was a condition that hardly existed. Today it is
on the rise and a major concern given the increasing number of patients with
dental implants. This study shows that Lactobacillus reuteri Prodentis is
effective in both the treatment and prevention of dental implant diseases and
will support the growth of BioGaia’s business in dental clinics around the
world”, says Peter Rothschild, President, BioGaia.
New confirming results in periodontitis
Another study with Lactobacillus reuteri Prodentis was also recently published,
in Journal of Clinical
Periodontology (http://www.ncbi.nlm.nih.gov/pubmed/25728888). This evaluated the
effects of Lactobacillus reuteri Prodentis as an adjunct to periodontal
treatment. It demonstrated that supplementation resulted in a lasting effect for
up to six months.
This is the fifth clinical study (Vivekananda 2010, Vicario 2012, Teughels 2013,
Szkaradkiewicz 2013) confirming that Lactobacillus reuteri Prodentis is
effective as an adjunct to standard periodontal treatment.
BioGaia ProDentis is a food supplement, which contains Lactobacillus reuteri
Prodentis. It is available in more than 20 countries (http://www.biogaia
-prodentis.com/).
Latest press releases from BioGaia
2015-02-23 BioGaia subsidiary Infant Bacterial therapeutics gets Orphan Drug
Designation in Europe
2015-02-12 BioGaia AB – Year-end report 2014
2015-02-10 Nestlé launches new product with BioGaia’s probiotic
BioGaia has published this information in accordance with the Swedish Securities
Market Act. The information was issued for publication on 9 March 2015, 09:00 am
CET.
For additional information please contact
Peter Rothschild, Chief Executive Officer, BioGaia: 46 8 555 293 00
BioGaia is a healthcare company that develops, markets and sells probiotic
products with documented health benefits. The products are primarily based on
the lactic acid bacterium Lactobacillus reuteri, which has probiotic, health
-enhancing effects. The class B share of the Parent Company BioGaia AB is quoted
on the Mid Cap list of the NASDAQ OMX Nordic Exchange Stockholm. www.biogaia.com
